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doi:10.1016/j.asjsur.2011.11.005Summary Objective: Based on a large series of histopathologically confirmed hepatic angio-
myolipomas, we retrospectively studied the typical diagnostic features of hepatic angiomyoli-
poma and proposed a treatment strategy for this disease.
Materials and methods: From December 1997 to December 2007, 74 consecutive patients who
received definitive treatment for hepatic angiomyolipoma, at a single tertiary center, were
studied.
Results: There was a marked female predominance (54 females vs. 20 males) and the mean
age was 42 years. Forty patients had no symptoms and the tumors were detected inciden-
tally during a medical check-up. From this study, we proposed the typical diagnostic
features of hepatic angiomyolipoma to be the absence of risk factors for malignancy,
normal tumor marker levels, and typical imaging features on ultrasound (USG), abdominal
contrast computed tomography (CT), or magnetic resonance imaging (MRI). Only 23% of
patients could have been diagnosed before surgery using these features. One patient
(1.4%) had a malignant angiomyolipoma, and died with distant metastases 14 months after
surgery. After a median follow-up of 64 months, there was no recurrence in the other 73
patients.
Conclusion: Patients with typical diagnostic features suggestive of hepatic angiomyolipoma
could be observed with regular surveillance. Definitive treatment should be performedDepartment of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical
(W.-P. Zhou).
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Treatment for hepatic angiomyolipoma 159when the tumor has symptoms/complications, when the tumor is enlarging, or when
a malignant lesion cannot be ruled out.
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reserved.1. Introduction
Angiomyolipoma occurs most commonly in the kidneys.
Hepatic angiomyolipoma represents the second most
common site of involvement. It is a rare, benign, hepatic
mesenchymal neoplasm, first described in 1976 by Ishak.1
Tuberous sclerosis is accompanied by renal angiomyoli-
poma in about 20% of patients.2 However, most patients
with hepatic angiomyolipoma do not have tuberous scle-
rosis. Most hepatic angiomyolipomas are small and asymp-
tomatic, but they can grow to a large size and thus mimic
a malignant tumor. They have an extremely low risk of
malignant transformation.3,4
Hepatic angiomyolipoma has three components: smooth
muscle cells, adipose tissue, and vessels. These components
can vary greatly within the tumor, and between different
tumors. The accuracy of preoperative diagnosis is very low
as a result of variable imaging appearances, due to the
varying proportion of the three components and the rarity of
hepatic angiomyolipoma.5e8 The definitive diagnostic study
remains the histopathological examination of the surgically
resected tumor, coupled with immunohistochemical anal-
ysis, specifically with homatropine methylbromide-45 (HMB-
45). The smooth muscle cells are the only specific and
diagnostic components of hepatic angiomyolipoma and are
characteristically immunostained positive for HMB-45 and
Melan-A.2,9,10
With advancements in imaging technology, hepatic angio-
myolipoma is being diagnosed with increasing frequency.
Overall, hepatic angiomyolipoma is a benign lesion with good
prognosis.2,11e14 If the diagnosis of hepatic angiomyolipoma
can be made, conservative treatment with regular surveil-
lance is recommended. Partial hepatectomy is only per-
formed when the tumor has symptoms/complications, when
it is enlarging, or when a malignant lesion cannot be ruled
out. However, hepatic angiomyolipoma poses a diagnostic
challenge clinically, radiographically, and morphologically.
Based on a large series of histopathologically confirmed
hepatic angiomyolipomas, the present study aimed to study
the typical diagnostic features of hepatic angiomyolipoma
and to propose a treatment strategy for this disease.
2. Methods
From December 1997 to December 2007, all patients with
hepatic angiomyolipoma who received curative treatment
with partial hepatectomy or local ablative therapy at the
Eastern Hepatobiliary Surgery Hospital (Shanghai, China),
were studied. The diagnoses were confirmed histopatho-
logically in all patients. Data on clinical features, serology,
tumor characteristics, preoperative imaging, and outcome
of treatment were collected prospectively and analyzed
retrospectively.2.1. Preoperative evaluation
All patients had a chest X-ray, ultrasonography (USG) of the
abdomen, and contrast computed tomography (CT) of the
abdomen or magnetic resonance imaging (MRI). Laboratory
blood tests including hepatitis B surface antigen, antibodies
to hepatitis C, serum alpha-fetoprotein (AFP), carcinoem-
bryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9),
serum albumin, serum total bilirubin, aspartate amino-
transferase (AST), alanine aminotransferase (ALT) and
prothrombin time were obtained, and the Pugh’s modifi-
cation of Child’s criteria was determined.15,16
2.2. Statistical analysis
Continuous data were expressed as mean  standard
deviation (SD) or median (range).3. Results
From December 1997 to December 2007, 74 consecutive
patients with hepatic angiomyolipoma received definitive
treatment. Patients and tumor characteristics are shown in
Table 1. There was a marked female predominance (54
females vs. 20 males) and the mean age was 42 years with
a range of 24e71 years. Forty patients had no symptoms
and were detected incidentally at a medical check-up. No
patients had tuberous sclerosis and renal angiomyolipoma.
Five patients were HBsAg positive. Serum AFP, CEA and
CA19-9 were normal in all patients.
All patients had USG examination. Fifty-eight patients
underwent both plain CT and intravenous contrast-
enhanced CT examination (Fig. 1) and 35 patients under-
went MRI examination (Fig. 2). After we analyzed our data,
we were able to suggest the diagnostic features of hepatic
angiomyolipoma (Table 2). Unfortunately, using these
criteria, only 23% of patients with hepatic angiomyolipoma
could be diagnosed before treatment.
Of the 74 patients, partial hepatectomy was carried out
in 73 patients and ultrasound-guided radiofrequency abla-
tion (RFA) after liver biopsy was carried out in one. For the
partial hepatectomy patients, 64 patients had Pringle
maneuver (mean vascular clamping time, 19.5  6.7
minutes) and 15 patients required intraoperative blood
transfusion. The mean  SD volume of intraoperative blood
loss was 392  54 mL. The overall complication rate and
hospital mortality rate were 24.8% and 0%, respectively
(Table 3). The postoperative hospital stay was 8.5  2.6
days.
The diagnoses were confirmed histopathologically, with
the presence of the specific and diagnostic components of
the smooth muscle cells and positivity for HMB-45. Only one
Table 1 Patient and tumor characteristics.
Age (y) 43.1  10.4
Sex (M:F) (n) 20:54
HBsAg positive (n) 5
Anti-HCV positive (n) 0
Liver cirrhosis (n) 3
Alcoholism (n) 7
Presentation (n)
No symptoms 40
Abdominal pain 19
Abdominal fullness 6
Palpable mass 6
Weight loss 3
Fever 0
Preoperative laboratory results
Hemoglobin (g/dL) 13.5  4.6
Platelet count (109/L) 186.1  48.3
Bilirubin (mmol/L) 14.2  5.3
Albumin (g/L) 40.2  8.3
Tumor markers, median (range)
AFP (ng/mL) 4 (0.1e8)
CEA (ng/mL) 2 (0e6)
CA19-9 (U/mL) 8 (0e23)
Size of tumor (cm)
<5 34
5e10 29
10.1e20 5
>20 4
Site of tumor (n)
Right hemi-liver 43
Left hemi-liver 23
Caudate lobe 7
Both hemi-livers 1
Figure 1 CT showing peripheral angiomyomatous component
with soft-tissue alternation, a fatty component and prominent
central vessels.
Figure 2 MRI showing peripheral angiomatous component,
a fatty component and prominent central vessels.
160 W.-G. Hu et al.female patient (1.4%) was found to have a malignant
angiomyolipoma after the operation. The pathological
features showed local infiltration and features of malig-
nancy. The surgical margins were clear. Three other
patients were found to have mitotic figures in the
specimens.
At the time of the census, seven patients (9%) were lost
to follow up. The median follow up was 64 months (30e120
months). Only the female patient with malignant angio-
myolipoma developed local and distant metastases 6
months after the operation and she died 14 months after
the operation. No tumor recurrence or metastasis was
found in the other patients during the follow-up period.
4. Discussion
Hepatic angiomyolipomas are rare, and altogether, only
approximately 200 cases have been reported in medical
literature. To the best of our knowledge, our cohort is the
largest reported.
Fat-containing tumors of the liver belong to a heteroge-
neous group of tumors with characteristic histopathologicalfeatures, variable tumor behavior, and variable imaging
findings. Fat can be present in a variety of benign and
malignant liver lesions. The presence of fat can allow
a specific diagnosis to be made, or narrow down the list of
differential diagnoses of liver lesions. Benign liver lesions
that contain fat include steatosis, adenoma, focal nodular
hyperplasia, lipoma, angiomyolipoma, cystic teratoma, and
hepatic adrenal rest tumor. Malignant liver lesions that can
contain fat, include hepatocellular carcinoma, primary and
metastatic liposarcoma, and hepatic metastases.5,6
Hepatic angiomyolipoma has three components: smooth
muscle cells, adipose tissue, and vessels (Fig. 3). These
components can vary greatly within the lesion, or between
lesions. The accuracy of preoperative diagnosis is very low,
as a result of the variable imaging appearances due to the
varying proportion of the three components and the rarity
of the tumor. Hepatic angiomyolipoma has usually been
misdiagnosed as other fat-containing tumors, particularly
Table 2 Diagnostic features of hepatic angiomyolipoma.
Absence of risk factors of liver malignancy
C No history of malignancy
C Hepatitis B or C negative
C No alcoholism
C No liver cirrhosis
Normal tumor markers
C AFP, CEA and CA19-9
Typical imaging features
C USG - a heterogeneously hyperechoic mass
C Plain CT scan - a heterogeneously low density mass with
low attenuation value (< 20 HU)
C Contrast-enhanced CT scan - marked enhancement of the
soft tissue components in the arterial phase and
enhancement in the portal venous phase
C MRI - presence of hypointensity or hyperintensity on
T1-weighted imaging and hyperintensity on T2-weighted
imaging
Figure 3 (A) Hepatic angiomyolipoma. (B) Cut surface
showing tumor with adipose tissue, large vessel spaces and
solid components of smooth muscle cells.
Treatment for hepatic angiomyolipoma 161hepatocellular carcinoma (HCC), as a significant overlap of
imaging features happens in more than 50% of patients.17
Hepatic angiomyolipoma poses a real diagnostic challenge.
Multiple modalities of tests have been used to aid in the
diagnosis of hepatic angiomyolipoma. Laboratory tests,
such as viral markers for hepatitis, tumor markers, and liver
function, have been negative or have not been proven to be
specific or helpful in the diagnosis of hepatic angiomyoli-
poma. Identification of fat within a liver lesion can be
critical in characterization of the lesion. Radiographically,
hepatic angiomyolipoma has the characteristic imaging
features of fatty tissue, yet the diagnosis is only correctly
suggested in a minority of cases. Although a combination of
USG, CT, MRI is able to increase the accuracy in preopera-
tive diagnosis, hepatic angiomyolipoma usually shows non-
typical patterns in imaging studies.7e10 The difficulty inTable 3 Treatment details and outcomes.
Treatment
Partial hepatectomy 73
RFA 1
Type of hepatectomy (n)
Wedge resection 7
Segmentectomy 11
Bi-segmentectomy 21
Right hepatectomy 17
Left hepatectomy 9
Left lateral sectionectomy 8
Complications (n)
Liver failure 0
Bleeding 0
Bile leak 0
Intra-abdominal collection/abscess 7
Pleural effusion 10
Procedure related mortality (n) 17imaging diagnosis occurs because of the wide variation
in the proportions of vessels, muscles, and fatty tissue in
different tumors. Consequently, hepatic angiomyolipoma
is difficult to diagnose on imaging studies alone. USG is
currently the first screening method for liver tumors, but
USG findings of most liver tumors are nonspecific. As
hyperechoic liver nodules cannot be characterized by USG,
subsequent examination using CT, MRI, or even fine-needle
aspiration cytology (FNAC) is necessary.18 CT, and MRI
typically demonstrate the fat component and prominent
central vessels. At CT scan, hepatic angiomyolipoma has
been reported to consist of two parts: a peripheral angio-
myomatous component with soft-tissue attenuation and
a fatty component with an attenuation value less than e20
HU.5e8 MRI characteristics vary, depending on the propor-
tion of intratumoral fat. Frequently, hepatic angiomyoli-
poma has a high fat content, with high signal intensity on
T1-weighted images and a significant drop in signal inten-
sity on fat-suppressed images.5e8 Diagnosis using FNAC or
biopsy is again difficult, because of the heterogeneity of
the lesion. The smooth muscle cells are the only specific
and diagnostic components of hepatic angiomyolipoma and
are characteristically immunostained positive for HMB-45
and Melan-A. This portion of tissue may or may not be
sampled. The definitive diagnostic tool remains the histo-
pathologic examination of the surgically resected spec-
imen, coupled with immunohistochemical staining.
Based on our study, only 23% of patients with hepatic
angiomyolipoma could have been reliably diagnosed before
162 W.-G. Hu et al.the operation. A preoperative diagnosis of hepatic angio-
myolipoma is difficult and its treatment remains controver-
sial. Hepatic angiomyolipoma is, in general, a benign lesion
with a good prognosis. In our series, only 1.4% of patients had
a malignant hepatic angiomyolipoma. In a patient without
risk factors for liver malignancy (such as chronic hepatitis B
or C carrier, liver cirrhosis, previous history of malignancy),
with negative serologic tumor markers, and with imaging
features suggestive of hepatic angiomyolipoma, conserva-
tive treatment with regular surveillance is recommended.
Partial hepatectomy should be performed when the tumor
has symptoms/complications, when the tumor is enlarging,
or when a malignant lesion cannot be ruled out.References
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